Nexien Biopharma Stock Current Valuation
| NXEN Stock | USD 0.01 0.00 0.00% |
Valuation analysis of Nexien Biopharma helps investors to measure Nexien Biopharma's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Nexien Biopharma's price fluctuation is out of control at this time. Calculation of the real value of Nexien Biopharma is based on 3 months time horizon. Increasing Nexien Biopharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Nexien Biopharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Nexien Pink Sheet. However, Nexien Biopharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.014 | Real 0.0115 | Hype 0.01 | Naive 0.0248 |
The intrinsic value of Nexien Biopharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Nexien Biopharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Nexien Biopharma helps investors to forecast how Nexien pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Nexien Biopharma more accurately as focusing exclusively on Nexien Biopharma's fundamentals will not take into account other important factors: Nexien Biopharma Company Current Valuation Analysis
Nexien Biopharma's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Nexien Biopharma Current Valuation | 2.58 M |
Most of Nexien Biopharma's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Nexien Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Nexien Biopharma has a Current Valuation of 2.58 M. This is 99.98% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The current valuation for all United States stocks is 99.98% higher than that of the company.
Nexien Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Nexien Biopharma's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Nexien Biopharma could also be used in its relative valuation, which is a method of valuing Nexien Biopharma by comparing valuation metrics of similar companies.Nexien Biopharma is currently under evaluation in current valuation category among its peers.
Nexien Fundamentals
| Return On Equity | -40.7 | |||
| Return On Asset | -5.99 | |||
| Current Valuation | 2.58 M | |||
| Shares Outstanding | 62.77 M | |||
| Shares Owned By Insiders | 54.17 % | |||
| Price To Book | 205.41 X | |||
| EBITDA | (563.99 K) | |||
| Net Income | (626.36 K) | |||
| Cash And Equivalents | 116.9 K | |||
| Total Debt | 221.73 K | |||
| Debt To Equity | 0.36 % | |||
| Current Ratio | 0.51 X | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (75.14 K) | |||
| Earnings Per Share | (0.01) X | |||
| Beta | 1.48 | |||
| Market Capitalization | 1.95 M | |||
| Total Asset | 124.52 K | |||
| Z Score | -8.4 | |||
| Net Asset | 124.52 K |
About Nexien Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Nexien Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nexien Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nexien Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Nexien Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Nexien Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nexien Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving against Nexien Pink Sheet
| 0.38 | LPCUF | Lees Pharmaceutical | PairCorr |
| 0.37 | BRK-A | Berkshire Hathaway | PairCorr |
| 0.37 | BRK-B | Berkshire Hathaway | PairCorr |
The ability to find closely correlated positions to Nexien Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Nexien Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Nexien Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Nexien Biopharma to buy it.
The correlation of Nexien Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Nexien Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Nexien Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Nexien Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Nexien Pink Sheet
Nexien Biopharma financial ratios help investors to determine whether Nexien Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nexien with respect to the benefits of owning Nexien Biopharma security.